Wall Street analysts expect Provention Bio Inc (NASDAQ:PRVB) to report earnings per share of ($0.28) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Provention Bio’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.30). Provention Bio reported earnings of ($1.05) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 73.3%. The business is expected to announce its next earnings results on Monday, August 12th.
On average, analysts expect that Provention Bio will report full-year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.24) to ($0.98). For the next financial year, analysts expect that the business will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.09) to ($0.78). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Provention Bio.
Provention Bio (NASDAQ:PRVB) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.11).
Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc purchased a new stake in shares of Provention Bio in the third quarter valued at $2,859,000. Vanguard Group Inc. purchased a new position in Provention Bio in the 3rd quarter worth about $2,859,000. Lido Advisors LLC purchased a new position in Provention Bio during the 4th quarter valued at about $47,000. Silverleafe Capital Partners LLC purchased a new position in Provention Bio during the 1st quarter valued at about $46,000. Finally, Alambic Investment Management L.P. purchased a new position in Provention Bio during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 1.74% of the company’s stock.
Shares of NASDAQ:PRVB opened at $3.77 on Tuesday. Provention Bio has a 52 week low of $1.52 and a 52 week high of $8.00. The firm has a market capitalization of $141.97 million and a P/E ratio of -3.17.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Featured Story: What type of investment options does a Roth IRA provide?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.